Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
- 23 July 2016
- journal article
- video audio-media
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 113,p. e54106
Abstract
Prion diseases result from the misfolding of the normal, cellular prion protein (PrPC) to an abnormal protease resistant isomer called PrPRes. The emergence of prion diseases in wildlife populations and their increasing threat to human health has led to increased efforts to find a treatment for these diseases. Recent studies have found numerous anti-prion compounds that can either inhibit the infectious PrPRes isomer or down regulate the normal cellular prion protein. However, most of these compounds do not cross the blood brain barrier to effectively inhibit PrPRes formation in brain tissue, do not specifically target neuronal PrPC, and are often too toxic to use in animal or human subjects. We investigated whether siRNA delivered intravascularly and targeted towards neuronal PrPC is a safer and more effective anti-prion compound. This report outlines a protocol to produce two siRNA liposomal delivery vehicles, and to package and deliver PrP siRNA to neuronal cells. The two liposomal delivery vehicles are 1) complexed-siRNA liposome formulation using cationic liposomes (LSPCs), and 2) encapsulated-siRNA liposome formulation using cationic or anionic liposomes (PALETS). For the LSPCs, negatively charged siRNA is electrostatically bound to the cationic liposome. A positively charged peptide (RVG-9r [rabies virus glycoprotein]) is added to the complex, which specifically targets the liposome-siRNA-peptide complexes (LSPCs) across the blood brain barrier (BBB) to acetylcholine expressing neurons in the central nervous system (CNS). For the PALETS (peptide addressed liposome encapsulated therapeutic siRNA), the cationic and anionic lipids were rehydrated by the PrP siRNA. This procedure results in encapsulation of the siRNA within the cationic or anionic liposomes. Again, the RVG-9r neuropeptide was bound to the liposomes to target the siRNA/liposome complexes to the CNS. Using these formulations, we have successfully delivered PrP siRNA to AchR-expressing neurons, and decreased the PrPC expression of neurons in the CNS.Keywords
This publication has 28 references indexed in Scilit:
- Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical diseaseActa Neuropathologica, 2010
- Optimization and characterization of anionic lipoplexes for gene deliveryJournal of Controlled Release, 2009
- Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion diseaseProceedings of the National Academy of Sciences, 2008
- Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected miceJournal of Clinical Investigation, 2006
- Killing the messenger: short RNAs that silence gene expressionNature Reviews Molecular Cell Biology, 2003
- Designing of ‘intelligent’ liposomes for efficient delivery of drugsJournal of Cellular and Molecular Medicine, 2002
- Neurons Are Protected from Excitotoxic Death by p53 Antisense Oligonucleotides Delivered in Anionic LiposomesJournal of Biological Chemistry, 2001
- Mice devoid of PrP are resistant to scrapieCell, 1993
- Normal development and behaviour of mice lacking the neuronal cell-surface PrP proteinNature, 1992
- Identification of a Protein That Purifies with the Scrapie PrionScience, 1982